CO-96 on a drug line: the drug is on the MAC's self-administered drug list

Why it lands on drug claims

The statute excludes from Part B drugs that "are usually self-administered by the patient" (Social Security Act §1861(s)(2)(A)); each MAC decides which drugs meet that test and publishes the list in a Billing & Coding article. A subcutaneous biologic the practice administers as a courtesy — an injectable the patient could give at home — is the classic case. Same drug, different jurisdiction, different answer.

Route decides it for some drugs. A drug the MAC lists as route-dependent is excluded when given subcutaneously and covered when given intravenously; the claim tells the contractor the route with JB (subcutaneous) or JA (intravenous). A route-dependent drug billed without the modifier, or with JB, returns CO-96 by design.

The practical consequence is that a SAD-listed drug belongs to Part D, not Part B. Because the exclusion is statutory, the patient is financially liable for it: bill the Part B line with the GY modifier (statutorily excluded) so it denies to patient responsibility, and bill the patient or route the drug through their Part D plan (pharmacy fill, brown-bag). An ABN is voluntary for a statutory exclusion, but a signed one avoids the argument later; GX marks a voluntary ABN on the line.

Same drug, different MAC: five codes the contractors disagree on

From each MAC's SAD exclusion article as last rebuilt on 2026-08-23. "Covered" = not on that MAC's list. Full list by state: SAD list.

The fix

• Check the drug against your MAC's current SAD list (the site's list is checked against the MAC articles weekly and rebuilt when one changes).
• Route-dependent drug given IV: add JA and resubmit as a corrected claim.
• Drug is on the list for the route given: the Part B claim is correctly denied. Route future doses through Part D (pharmacy fill, brown-bag) or the manufacturer's program.
• Bill the line with GY (statutorily excluded) so the denial carries patient responsibility; a voluntary ABN, marked GX, is optional but useful. GA is for a required ABN on a medical-necessity denial, not this case.

What to attach

• For appeals only where the drug is not on your MAC's list: the MAC's SAD article showing the drug absent
• For JA resubmissions: the administration record showing the IV route
• For patient billing: the GY-modified line on the remit showing patient responsibility

Corrected claim or appeal?

Usually neither. A route-dependent drug given IV: corrected claim with JA. A drug on your MAC's list for the route given: the denial stands, the amount is the patient's (bill with GY), and future doses go through Part D or the manufacturer program. Appeal only when the drug is not on your MAC's list.

Medicare windows (redetermination 120 days, reconsideration 180 days, ALJ 60 days) and the commercial path are on the denials hub, cited to 42 CFR Part 405 Subpart I; the edits are CMS's NCCI tables.